Immunotherapy, such as programmed death-1 (PD-1), programmed death ligand-1 (PD-L1), and cytotoxic T lymphocyte-associated antigen 4 inhibitors, have shown promising results in melanoma, renal cancer, NSCLC, and other tumors (Garon et al., 2015; Larkin et al., 2015; Motzer et al., 2015). This evidence concerns the gene CD274 and non-small cell lung carcinoma.